The kynurenine pathway in pediatric "mild-to-moderate" traumatic brain injury: translational insights from a

Harm J van der Horn1, Koen Visser1, Tracey V Wick2

  • 1Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

PubMed

Insights

Pediatric traumatic brain injury (TBI) alters the kynurenine pathway (KP) long-term in humans, with lower tryptophan and related metabolites linked to persistent symptoms. Animal models showed different results, emphasizing biomarker relevance in TBI research.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Clinical Medicine

Background:

  • Pediatric traumatic brain injury (TBI) necessitates understanding biochemical pathways for effective biomarker discovery.
  • The kynurenine pathway (KP), involved in tryptophan metabolism, is linked to neuroinflammation and TBI.
  • Identifying blood-based biomarkers is crucial for precision medicine and clinical trials in pediatric TBI.

Purpose of the Study:

  • To investigate the biochemical alterations in the kynurenine pathway (KP) following pediatric mild TBI (pmTBI) in humans.
  • To examine the temporal dynamics of KP metabolites in a large-animal model of mild-to-moderate TBI (mmTBI).
  • To correlate KP metabolite levels with persistent post-concussive symptoms (PCS) in pediatric TBI patients.

Main Methods:

  • Serum samples from 54 human pmTBI patients and 38 healthy controls (HC) were analyzed using liquid chromatography-tandem mass spectrometry.
  • KP metabolites and inflammatory markers were measured at ~7 days and ~4 months post-injury in humans.
  • KP metabolites and inflammatory markers were assessed in 33 juvenile swine with mmTBI and 10 sham animals at multiple time points post-injury.

Main Results:

  • Human pmTBI patients showed significantly lower concentrations of tryptophan (Trp), 3-hydroxykynurenine (3HK), 3-hydroxyanthranilic acid (3HA), xanthurenic acid (XA), and picolinic acid (PA) compared to HC, with effects more pronounced at 4 months.
  • Lower levels of Trp, 3HA, and XA at 4 months post-injury were associated with persistent post-concussive symptoms (PCS).
  • The large-animal model exhibited an increased anti-inflammatory response (IL-1RA) but no significant changes in KP metabolites, with temporal changes likely influenced by anesthesia.

Conclusions:

  • Pediatric TBI has long-lasting effects on the kynurenine pathway in humans.
  • Discrepancies between human and animal model findings underscore the need for clinically relevant biomarkers in preclinical TBI research.
  • KP metabolite profiling holds potential for identifying biomarkers of persistent symptoms after pediatric TBI.